ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...
How to Fix an Overactive Bladder
These strategies are effective at stopping leaksBy Ashley AbramsonBladder leaks can be disruptive—and they’re very common. Up ...
European Medical Journal5d
Treatment Advances in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...
HealthDay on MSN3d
Bladder Wall Thickness Reflects Severity of Bladder Inflammatory Conditions
Findings in patients with interstitial cystitis/bladder pain syndrome can help with diagnosis of interstitial cystitis subtypes ...
Tahoe Daily Tribune8d
Is your bladder trying to tell you something?
Millions of adults have bladder problems. Some people have sudden, strong urges to urinate or an uncontrollable flow. Others ...
European Medical Journal13d
Exploring Bladder Preservation in Muscle-Invasive Bladder Cancer Treatment
Discover a study that found that the combination of durvalumab and tremelimumab with concurrent radiotherapy is a feasible ...
CURE2d
Blue Light Cystoscopy Reduces Recurrence in High-Risk Bladder Cancer
Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in ...
CURE3d
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
UroToday2d
SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Joon Kyung Kim discussing an evaluation of ...
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...